Effects of eplerenone and salt intake on left ventricle remodeling after myocardial infarction in rats

Hypertension Research

Volumn 29, Issue 8, 2006, Pages 627-634

  Urabe, Akihiro ^a   Izumi, Takehiko ^a   Abe, Yuichi ^a   Taniguchi, Ikuo ^a   Mochizuki, Seibu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Left ventricular remodelling; Myocardial infarction; Salt intake; Selective aldosterone blocker

Indexed keywords

ALDOSTERONE; EPLERENONE; SODIUM CHLORIDE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MORPHOLOGY; NONHUMAN; RANDOM SAMPLE; RAT; SALT INTAKE; TREATMENT DURATION;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CARDIOMEGALY; DIET, SODIUM-RESTRICTED; ECHOCARDIOGRAPHY; FIBROSIS; FOOD-DRUG INTERACTIONS; HEART; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; SODIUM CHLORIDE; SPIRONOLACTONE; VENTRICULAR REMODELING;

EID: 33748929162     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.627     Document Type: Article

References (32)

1. Pitt B, Zannad F, Remme WJ, et al, Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
2. Pitt B, Remme W, Zannad F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
3. Brown NJ: Eplerenone: cardiovascular protection. Circulation 2003; 107: 2512-2518.
4. Takeda Y: Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res 2004; 27: 781-789.
5. Young M, Funder JW: Eplerenone, but not steroid with-drawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 2004; 145: 3153-3157.
6. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836.
7. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212-2216.
8. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303-310.
9. Conlin PR: Interactions of high salt intake and the response of the cardiovascular system to aldosterone. Cardiol Rev 2005; 13: 118-124.
10. Funder J: Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001; 28: 1002-1006.
11. Yoshida K, Kim-Mitsuyama S, Wake R, et al: Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28: 447-455.
12. Martinez DV, Rocha R, Matsumura M, et al: Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002; 39: 614-618.
13. Lal A, Veinot JP, Leenen FH: Prevention of high salt diet - induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens 2003; 16: 319-323.
14. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H: Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005; 28: 925-936.
15. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL: Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2004; 43: 1252-1257.
16. Izumi T, Saito Y, Kishimoto I, et al: Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 2001; 108: 203-213.
17. Tanaka Y, Nagai M, Date T, et al: Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 2004; 27: 865-875.
18. Delyani JA, Robinson EL, Rudolph AE: Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001; 281: H647-H654.
19. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003; 42: 1666-1673.
20. Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120: 893-901.
21. Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992; 26: 671-677.
22. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P: Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990; 65: 1G-7G.
23. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583.
24. Rocha R, Rudolph AE, Frierdich GE, et al: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.
25. Rogacz S, Williams GH, Hollenberg NK: Time course of enhanced adrenal responsiveness to angiotensin on a low salt diet. Hypertension 1990; 15: 376-380.
26. Yoshimura M, Nakamura S, Ito T, et al: Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002; 87: 3936-3940.
27. Suzuki G, Morita, Mishima T, et al: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002; 106: 2967-2972.
28. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H: Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000; 36: 495-500.
29. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H: Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000; 141: 1901-1904.
30. Ye P, Kenyon CJ, Mackenzie SM, et al: The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart. Endocrinology 2005; 146: 5287-5293.
31. Fujisawa G, Okada K, Muto S, et al: Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury. Hypertension 2003; 41: 493-498.
32. 2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 2005; 146: 973-980.